Journal of Current Ophthalmology

Corneal Endothelial Health after Phacoemulsification Cataract Surgery without Viscoelastic Substance

German R Bianchi, MD

A study of 1,324 eyes undergoing cataract surgery without viscoelastic substance (VS) showed a 9.4% decrease in endothelial cell density (ECD) and a 1.2% increase in central corneal thickness (CCT) one year after surgery. The majority of changes occurred within the first six months, and no significant complications were reported. The results suggest that phacoemulsification cataract surgery can be safely performed without VS, with minimal impact on corneal health.

Purpose:

To evaluate corneal endothelial health after cataract surgery without viscoelastic substance (VS).
Methods:
A prospective, non-randomized, case‑series study was developed, and phacoemulsification cataract surgery without VS was performed on 1324 eyes between September 2015 and September 2018. As main outcomes, mean endothelial cell density (ECD) and mean central corneal thickness (CCT) were assessed before surgery and then 6 and 12 months after surgery. Data are summarized as mean, standard deviation (SD), and 95% confidence intervals (CI).

Results:

A total of 1324 eyes were operated, and 31 were excluded by intraoperative complications. The mean ECD baseline was 2506 cells/ mm2 (SD = 215, CI = 2494–2518); 6 months after surgery, it was 2328 cells/mm2 (SD = 213, CI = 2316–2340); and 1 year after surgery, it was 2265 cells/mm2 (SD = 214, CI = 2253–2277). In terms of percentage differences, the mean ECD decrease was 9.4% after 1 year. The mean preoperative CCT was 531.6 μm (SD = 34.8, CI = 529.7–533.5); 6 months after surgery, it was 537.7 μm (SD = 38.2, CI = 535.6–539.8); and 1 year after surgery, it was 537.9 μm (SD = 37.9, CI = 535.8–540.0). The mean CCT increased 1.2% 1 year after surgery.

Conclusions:

Phacoemulsification cataract surgery can be completely performed without VS, with very low intraoperative complications.
The postoperative ECD and CCT changes occurred primarily during the first 6 months, and the changes decreased during the

STAY INFORMED

Signup to get the first look at new products, publications, and events

Related publications

Eye

Nature Eye

Clinical outcomes with a new diffractive multifocal intraocular lens optimized by the dynamic light utilization algorithm

Jorge L. Alió 1,2, Elinor Megiddo Barnir1,3,4, Ronald Steven S. Medalle II 1,5,6, Ana B. Plaza-Puche1, Antonio Martínez1, Pilar Yébana1, Blanca Poyales7 and Francisco Poyales7
This study assessed the refractive outcomes, optical performance, and quality of vision in patients implanted with the Intensity Hanita diffractive intraocular lens (IOL). The prospective, observational study included 64 eyes that underwent bilateral cataract surgery with Intensity IOL implantation, with evaluations conducted at 6 months post-surgery. Results indicated that 66% of eyes achieved uncorrected distance visual acuity (UDVA) of 0.10 logMAR or better. The defocus curve showed optimal vision at distance (0.02 ± 0.07 logMAR at 0.0 D) with stable performance through intermediate and near vision ranges (0.11 ± 0.08 logMAR at -1.5 D, 0.12 ± 0.12 logMAR at -2.5 D). Contrast sensitivity remained stable (p ≥ 0.06), and high-order aberrations were low, with a Strehl ratio of 0.12 ± 0.04. Mild halos and glare were reported but did not interfere significantly with daily activities, and the near activity visual questionnaire (NAVQ) indicated high patient satisfaction with near-vision tasks. These findings support the Intensity Hanita IOL’s effectiveness in providing clear vision across all distances through a five-foci distribution design that enhances depth of focus.

BMC Ophthalmology

Clinical results with a multifocal intraocular lens with a novel optical design

Gustavo Goldman
This study examined the optical performance and safety of a newly designed multifocal intraocular lens (IOL) with five focal points (two additional "intensifiers") for cataract and presbyopia management. Conducted in Buenos Aires and Ramos Mejia, Argentina, the prospective, non-randomized observational study included 31 patients (61 eyes) who received bilateral implantation between March 2020 and November 2021. At the 3-month follow-up, all eyes achieved an uncorrected distance visual acuity (UCDVA) of at least 0.15 logMAR, with 93% achieving 0.1 logMAR and 44% achieving 0.0 logMAR. For intermediate vision at 80 cm, 98% of eyes achieved at least 0.1 logMAR, and 79% reached 0.0 logMAR. The results highlight the new multifocal IOL’s efficacy, particularly for intermediate and near vision, with high rates of spectacle independence and patient satisfaction.
Highlights of Ophthalmology

HIGHLIGHTS OF OPHTHALMOLOGY

Short-Term Visual Outcomes After Bilateral Pentafocal Intraocular Lens Implantation. A Pilot Study

Kepa Balparda, MSc PhD, Laura Zharick Ortega-Quiroga, MD, Mariana Escobar-Giraldo, MD, Daniela Ortiz-Piedrahíta, Isabela Franco-Sánchez, Tatiana Herrera-Chalarca, BSc.
This study aimed to assess the short-term refractive and visual outcomes following the implantation of the Hanita Intensity SL pentafocal intraocular lens (IOL) in patients with presbyopia. In a retrospective observational review, 20 eyes from 10 patients (70% female) who underwent immediate sequential bilateral surgery were evaluated over three months. Results showed that 100% of patients achieved visual acuity of 20/25 or better for both near and far distances, and 20/40 or better for intermediate distances. The defocus curve indicated excellent visual performance from infinity to approximately 33 cm, allowing functional vision at all distances. Additionally, all patients reported complete independence from glasses. These findings suggest that the Hanita Intensity SL IOL is a safe and effective option for achieving spectacle independence in presbyopic patients.

Fill in the details and receive the presentation

Skip to content